

Approved by PCI and Affiliated to Camania University, Hyderabad.
Accredited by NDA-UG Program, NAAC A+ Grade.
Recognition of College under Section 2(f) of the UGC Act 1956,
UGC Autonomous Institution



# M.Pharmacy (Pharmacology) II Semester (PCI) (Supply) Examination Dec / Jan 2024-25

Subject: ADVANCED PHARMACOLOGY-II & MPL201T

Time: 3 Hours

Max.Marks: 75

#### PART- A

Note: Answer any FIVE questions. All questions carry equal marks.

ON	Overtion	Marks	CO	BL
Q.No.	Question  a).Explain the biosynthesis ,storage and transport of thyroid hormones.  Explain pharmacology of lodine trapping inhibitors.	8M	1	2
	b) Write short notes on sex hormones.	7M	1	3
2	a). Explain the role alkylating agents in the treatment of cancer.	8M	3	2
	b).List out protozoal infections. Explain the treatment of ameobiasis with suitable examples of drugs.	7M	3	1
3	a).Define Aminoglycosides ?. Explain antibacterial spectrum, MOA and therapeutic uses of streptomycin.	8M	1 1 3	1
	b). Write detailed notes on Mechanism of action, adverse effects and therapeutic uses of first generation cephalosporins	7M	(45) 5(P	3
4	a).Explain the treatment of COPD.	7M	3 4 5	2
	b) .Write notes on treatment of irritable bowel syndrome.	8M		3
5	a). Write notes on role of free radicals in etiopathology of diabetes	7M	5	3
	b).Explain the advanced treatment for Alzheimer's disease	8M	101	2
6	a). Explain the role of anti oxidants in the regulation of free radical activity	7M	5	2
	b). Write notes on advances in the treatment of Parkinson's disease	8M	1 1 3 2 2 2 3 4 5 5 5 4 4	3
7	a). Write notes on applications of chronotherapy in diabetes	8M	4	3
	b). Write detailed notes on pharmacology of Domperidone	7M	4	3
8	a).Classify quinolones.Expalin about anti bacterial spectrum, MOA of any one from quinolones	8M	2	3
	b). Write detailed notes on corticosteroids	7M	1	3



Approved by PCI and Affiliated to Camania University, Hyderabad.
Accredited by NBA-UG Program, NAAC A+ Grade,
Recognition of College under Section 2(f) of the UGC Act 1956,
UGC Autonomous Institution



# M.Pharmacy (Pharmacology) II Semester (PCI) (Main) Examination Jul/Aug 2024


Subject& Code: Pharmacological and Toxicological Screening Methods-II & MPL202T Time: 3 Hours


Max.Marks: 75

Note: Answer any FIVE questions. All questions carry equal marks.

Q.No.	Question	Marks	CO	BL
1	a) Explain the role of toxicology in drug development and describe the	8	1	2
	types of toxicology. b) What are the OECD principles of Good Laboratory Practice (GLP) and why are they important in drug development?	7	3	1
2	a) Compare and contrast acute, sub-acute, and chronic toxicity studies for	8	1	2
2	oral routes as per OECD guidelines.  b) Analyze the methodologies and regulatory requirements for acute eye irritation studies as per OECD guidelines.	7	1	4
3	a) What is reproductive toxicity? Describe the study design and significance of male reproductive toxicity studies.	8	2	1
	b) Compare and contrast different genotoxicity studies.	7	2	2
4	<ul><li>a) Define IND and discuss the significance and industry perspective of IND enabling studies.</li><li>b) What are Tier 1 safety pharmacology studies, and why are evaluations of CVS, CNS, and respiratory systems important in drug development?</li></ul>	7	4	2
5	a) Define toxicokinetics and explain its role in preclinical studies. How	8	5	1,2
2	does toxicokinetic evaluation differ from pharmacokinetic evaluation? b) Propose alternative methods to animal toxicity testing and evaluate its advantages and limitations.	7	5	6
6	<ul><li>a) Discuss about dermal toxicity studies.</li><li>b) Explain in vivo carcinogenicity studies and explain their role in</li></ul>	7	2	2
	regulatory toxicology. Which animals are commonly used in these studies?	8	2	2
7	<ul> <li>a) Evaluate the procedures and importance of dermal irritation studies as per OECD guidelines.</li> </ul>	8	1	5
	b) Examine the ethical concerns of safety pharmacology studies. How can risks to animals be reduced while ensuring reliable data for regulatory approval?	7	1	4
8	a) What are the key regulatory guidelines provided by ICH for conducting toxicity studies?	8	1	1
	b) Discuss the applications of toxicokinetics.	7	5	2

Code. No.M7082423





### M.Pharmacy (Pharmacology) II Semester (PCI) (Main) Examination Jul/Aug 2024


Subject & Code: PRINCIPLES OF DRUG DISCOVERY & MPL 203T

Max.Marks: 75 Time: 3 Hours

Note: Answer any FIVE questions. All questions carry equal marks.

Q.No.	Question	Marks	CO	BL
1	a) Explain lead identification and optimization	10	3	2
	b) Write the role of protein microarrays in target discovery	5	3	3
2	a) Discuss the Economics of drug discovery	10	3	2
	b) Discuss the use of X-ray crystallography in protein structure prediction	5	3	2
3	a) Explain Insilco lead discovery techniques	8	4	2
	b) Discuss structure based approaches in rational drug design	7	4	2
4	a)Outline motifs and folds in protein structure	5	2	1
	b) Explain various steps in threading modelling	10	2	2
5	a) Describe the role of combinatorial chemistry lead identification	5	4	2
(	b) Describe docking based screening	5	4	2
	c) Explain process manual docking	5	3 3 3 4 4 2 2	2
6	a) Compare and contrast between SAR and QSAR	10	5	4
	b) Outline rigid docking	5	5	4
7	a) Appraise the value of regression analysis in drug discovery	5	4	5
	b) Assess the difference between SAR and QSAR	10	4	5
8	a) Formulate rationale of prodrug design	8	1	6
	b) Design sustained drug action	7	1	6

Code. No. M7082424



Approved by PCI and Affiliated to Osmania University, Hyderabad.
Accredited by NBA-UG Program, NAAC A+ Grade.
Recognition of College under Section 2(f) of the UGC Act 1956,
UGC Autonomous Institution



# M.Pharmacy (Pharmacology) II Semester (PCI) (Main) Examination Jul/Aug 2024


Subject & Code: CLINICAL RESEARCH AND PHARMACOVIGILANCE & MPL 204 T

Time: 3 Hours Max.Marks: 75

Note: Answer any FIVE questions. All questions carry equal marks.

Q.No.	Question	Marks	CO	BL
1	a) Explain the principles of ICH-GCP guidelines. b) Describe the Schedule Y guidelines in clinical trials.	8 7	1	2
2	a) Write the composition and responsibilities of IRB.     b) Explain the roles and responsibilities of Clinical Investigator.	8 7	3	2 3
3	<ul> <li>a) Discuss the various steps involved in preparing a protocol.</li> <li>b) Write in detail about international classification of diseases.</li> </ul>	8 7	1	2 3
4	What are the differences in Indian and Global pharmacovigilance requirements?	15	5	4
5	<ul><li>a) Define ADR. Classify with examples.</li><li>b) Write about the predictability and preventability assessment of ADR.</li></ul>	8 7	6	1 2
6	Write a note on a) Observational studies b) Spontaneous reporting system	8 7	2	3
7	<ul><li>a) Explain the methods of safety monitoring in clinical trails</li><li>b) What are the various statistical methods for evaluating medication safety data.</li></ul>	8 7	4	3
8	Discuss the following  a) Declaration of Helsinki  b) Vaccine safety surveillance  c) Pharmacoeconomics	5 5 5	1	3





## M.Pharmacy (Pharmacology) II Semester (PCI) (Main) Examination Jul/Aug 2024

Subject& Code: ADVANCED PHARMACOLOGY-II & MPL201T

PART- A

Max.Marks: 75 Time: 3 Hours

Note: A	nswer a	ny FIVE questions. All questions carry equal marks.		60	DI
Q.No.	Questio	nn	Marks	CO	BL 3
1	a)	Write brief notes on pathophysiology of tuberculosis. Explain the treatment of tuberculosis according to Revised National		2,3	3
	b)	Tuberculosis Control Programme (RNTCP) guidelines.  What are beta lactam antibiotics? Explain the pharmacology of any one beta lactam antibiotics.	8	3	2
2	a)	Classify anti-cancer drugs. Explain about MOA, pharmacokinetics and therapeutic uses of Pyrimidine antagonists	8	3	3
	b)	like cancer	7	5	2
3	a)	Write down the applications of chronopharmacology in cardiovascular diseases.	7	4	2
	b)	Classify Anti-ulcer drugs Explain the role of Proton Pump Inhibitors in the treatment of Peptic-ulcer Write brief notes on factors mediating to cause bronchial asthma	8	4	3
4	a)	and role of sympathonimenc treatment of asthma?	8	3	3
	b)	Define immunostimulants. Explain the role immunostimulants in improving immunity with examples.	7	3	1
5	al)	fungal infection.	7	2	3
	VI.	What are macrolide antibiotics? Explain pharmacology of any one macrolide antibiotic?	8	2	2
6	a)	Explain therele of insulin in the regulation of glucose level and its metabolic functions	7	1	2
	b)	Classify oral hypoglycemic agents. Write brief notes on pharmacology of biguanides	8	1	3
7	a)	i - ith suitable ayammla	7	1	3
	b	Classify anti thyroid drugs. Write brief notes on iodide trapping inhibitors	8	1	3
8	a	Write notes on drugs used in the treatment of helminthiasis.	7	3	3
	b	Classify immunosuppressants. Explain MOA, Adverse effects and therapeutic uses of Calcineurin inhibitors	8	3	3